Favrille to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Year End 2007 Financial Results on February 19, 2008

... SAN DIEGO Feb. 5 /- Favrille Inc. (Nasdaq...A live audio webcast of management's presentation will be available on...About Favrille Inc. ...Favrille Inc. is a biopharmaceutical company focused on thedevelopme...

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq:
FVRL), a biopharmaceutical company developing patient-specific, active
immunotherapies for the treatment of cancer, announced today that it will
host a conference call and live webcast at 5:00 p.m. Eastern Time on
Tuesday, February 19, 2008 to discuss the Company's fourth quarter and year
end 2007 financial results. A press release will be issued before the U.S.
stock markets open that morning.

A live audio webcast of management's presentation will be available on
the Investor Relations section of the Company's web site at
http://www.favrille.com. Alternatively, callers may participate in the conference
call by dialing (888) 713-4213 or (617) 213-4865, passcode 19388148. To
pre-register for this call, please go to
https://www.theconferencingservice.com/prereg/key.process?key=P9YHNKNHB.
Callers who pre-register will be given a unique PIN to gain immediate
access to the call and bypass the live operator. You may pre-register at
any time, including up to and after the call start time. A telephone replay
of the call will also be available for 48 hours. The telephone replay can
be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 99385491.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the
development and commercialization of targeted immunotherapies for the
treatment of cancer and other diseases of the immune system. The Company's
lead product candidate, Specifid(TM) (formerly FavId(R)), is based upon
unique genetic information extracted from a patient's tumor. Specifid is
currently under investigation in a pivotal Phase 3 clinical trial for
patients with follicular B-cell non- Hodgkin's lymphoma (NHL) and Phase 2
clinical trials in other B-cell NHL indications. The Company is developing
additional applications based on its immunotherapy expertise and
proprietary cost-effective manufacturing technology, including a second
product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...

(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...

(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...

(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...

(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...

(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...